Evidence map›Paper›PMID 41200180›Full record

ReviewFrontiers in immunology2025

Roles of nucleotide metabolism in pancreatic cancer.

Quanlin Liu, Jiahua Liu, Shige Wang, Nabuqi Bao, Xinya Zhao, Lei Wang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Quanlin Liu *First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jiahua Liu *First Affiliated Hospital of Dalian Medical University, Dalian, China.
Shige Wang *Jinqiu Hospital, Shenyang, China.
Nabuqi BaoFirst Affiliated Hospital of Dalian Medical University, Dalian, China.
Xinya ZhaoFirst Affiliated Hospital of Dalian Medical University, Dalian, China.
Lei WangFirst Affiliated Hospital of Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleotide metabolism plays a pivotal role in the onset and progression of various human diseases, including pancreatic disorders. As fundamental biomolecules, nucleotides are essential for DNA and RNA synthesis, energy production, and cell signaling. Disruptions in nucleotide metabolic pathways have been linked to altered cell proliferation, apoptosis, and immune responses-critical processes in the development of pancreatic diseases. In pancreatic cancer, metabolic changes in nucleotides facilitate rapid tumor cell proliferation and enhance chemotherapy resistance. Recent studies have concentrated on identifying specific enzymes and pathways within nucleotide metabolism as potential therapeutic targets. Targeted interventions, such as modulating RRM2, TS, and other key enzymes or disrupting the PI3K/AKT/mTOR pathway, have demonstrated potential in reducing tumor growth and inflammation in pancreatic tissue. This review provides an overview of the latest advancements in the understanding of nucleotide metabolism in pancreatic cancer pathogenesis, emphasizing diagnostic and therapeutic strategies that may improve patient outcomes.

Indexed as

NucleotidesPancreatic NeoplasmsAnimalsHumansSignal TransductionNucleotidesimmune microenvironmentKRAS mutationmetabolic reprogrammingnucleotide metabolismpancreatic cancerpathogenesistherapeutic targets

Identifiers

PMID41200180
PMCPMC12585966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.